ZNTL News and Press, Zentalis Pharmaceuticals Inc.

Rapid oral presentation to highlight overall survival data from the DENALI Part 1b study of azenosertib SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Zentalis ®  Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational f...

Appointments enhance commercialization readiness as Zentalis advances registrational program for azenosertib in Cyclin-E1 positive platinum-resistant ovarian cancer  SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innov...

2026-05-22 08:15:09 ET H.C. Wainwright analyst issues BUY recommendation for ZNTL on May 22, 2026 10:56AM ET. The previous analyst recommendation was Buy. ZNTL was trading at $4.14 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...

In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse events Activity of the combined regimen across all dose cohorts achieved 39% ORR and 7.3-month median PFS In the 250 mg QD 5:2 interm...

2026-05-12 16:46:04 ET More on Zentalis Pharmaceuticals Seeking Alpha’s Quant Rating on Zentalis Pharmaceuticals Historical earnings data for Zentalis Pharmaceuticals Financial information for Zentalis Pharmaceuticals Read the full article on Seeking...

400mg QD 5:2 selected as azenosertib monotherapy pivotal study dose based on favorable benefit-risk profile in DENALI Part 2a, supporting advancement in registration-intended trials DENALI Phase 2 trial topline readout expected by year-end 2026, with potential to support accelerated approval pat...

Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy now enrolling ASPENOVA designed as confirmatory study to support DENALI Phase 2 accelerated approval pathway, pending FDA feedback SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Zentalis ® P...

SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today annou...

Preclinical data show encouraging activity of azenosertib combinations in ADC-resistant TNBC, supporting the potential for pipeline expansion beyond ovarian cancer Real-world data demonstrate Cyclin E1-positive ovarian cancer patients have significantly worse outcomes, independent of CCNE1 ge...

2026-04-09 13:39:23 ET Denver, Colorado - Onconetix (NASDAQ:ONCO) emerged as the session’s top gainer after touching an intraday high of $2.82. The move followed renewed attention around its pending acquisition of Realbotix LLC and the debut of the Vinci AI Vision System, a devel...